BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34001017)

  • 1. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
    Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
    BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
    Idvall I; Andersson C; Fallenius G; Ingvar C; Ringberg A; Strand C; Akerman M; Fernö M
    Acta Oncol; 2001; 40(5):653-9. PubMed ID: 11669340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal carcinoma
    Zhu M; Kuang Y; Jiang Z; Liu J; Zhang H; Zhao H; Luo H; Chen Y; Peng Y
    Gland Surg; 2024 Apr; 13(4):512-527. PubMed ID: 38720675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
    Schorr MC; Pedrini JL; Savaris RF; Zettler CG
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
    Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
    J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
    Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
    Yan M; Bomeisl P; Gilmore H; Harbhajanka A
    Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
    Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
    Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.
    Zhou H; Yu J; Wang X; Shen K; Ye J; Chen X
    Sci Rep; 2022 Feb; 12(1):2169. PubMed ID: 35140303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.
    Wang X; Liu D; Zeng X; Jiang S; Li L; Yu T; Zhang J
    Cancer Imaging; 2021 Jan; 21(1):4. PubMed ID: 33413654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.